Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aclara Biosciences (ACLA) - The next small thing? -- Ignore unavailable to you. Want to Upgrade?

To: Larry Livingston who wrote (4)	10/3/2000 12:01:23 PM
From: Larry Livingston	Read Replies (1) \| Respond to of 16

"Take Aclara BioSciences (ACLA:Nasdaq - news). Investors who bought into this biochemical analysis company before its IPO will be free to sell nearly 70% of its stock, about 23.7 million shares, starting Sept. 18, according to unlockdates.com, a Web site that tracks such matters. And given Aclara's stellar IPO, more than tripling from the stock's offering price of 21 in March, it seems likely that early investors will be looking to cash in a hefty portion of their stake. The stock closed at 46 5/8 Thursday, more than double the offer price. " From: Unlocking Biotech IPOs May Unhinge Sector's Rebound By Dane Hamilton Staff Reporter 8/24/00 6:58 PM ET TheStreet.Com